Quell Therapeutics Funding: $344M Raised, Series B (2021)
Quell Therapeutics is based in London, United Kingdom. It has raised $344M in total funding. Latest round: Series B.
Quell Therapeutics funding overview
Quell Therapeutics is based in London, United Kingdom. Quell Therapeutics has raised $344M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series B announced in November 2021. The round record for Quell Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include Syncona, UCL Technology Fund, Fidelity Management & Research Company, Ridgeback Capital, Jeito Capital, SV Health Investors and 3 others. 9 distinct backers are named across the disclosed rounds.
Quell Therapeutics at a glance
Total raised
$344M
Latest round
Series B
Latest round date
November 2021
Headquarters
London, United Kingdom
Notable investors
Syncona, UCL Technology Fund, Fidelity Management & Research Company, Ridgeback Capital, Jeito Capital, SV Health Investors, AstraZeneca, British Patient Capital
Frequently asked about Quell Therapeutics funding
How much has Quell Therapeutics raised?
Quell Therapeutics has raised $344M in total disclosed funding across the rounds on record.
Who has invested in Quell Therapeutics?
Syncona, UCL Technology Fund, Fidelity Management & Research Company, Ridgeback Capital, Jeito Capital, SV Health Investors are named among the investors backing Quell Therapeutics.
What was the latest Quell Therapeutics funding round?
The most recent disclosed round is a Series B, announced in November 2021.
Where is Quell Therapeutics based?
Quell Therapeutics is based in London, United Kingdom.
When did Quell Therapeutics last raise?
The last disclosed Quell Therapeutics round closed in November 2021 at Series B.
Every Quell Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in London at a similar stage.
